“Plasma Exosome-Derived Fragile Site-Associated Tumor Suppressor As a Powerful Prognostic Predictor for Patients With Ovarian Cancer”. 2022. Biomolecules and Biomedicine 22 (3): 453-59. https://doi.org/10.17305/bjbms.2021.6404.